Update on Medical Management of Pulmonary Arterial Hypertension

Alexander E Sherman; Rajan Saggar; Richard N Channick

doi:10.1016/j.ccl.2021.08.002

Update on Medical Management of Pulmonary Arterial Hypertension

Cardiol Clin. 2022 Feb;40(1):13-27. doi: 10.1016/j.ccl.2021.08.002.

Authors

Alexander E Sherman¹, Rajan Saggar², Richard N Channick³

Affiliations

¹ Division of Pulmonary, Critical Care, Sleep Medicine, Clinical Immunology and Allergy, David Geffen School of Medicine at UCLA, 650 Charles E. Young Drive South 43-229 CHS, Los Angeles, CA 90095-1690, USA.
² Pulmonary Vascular Disease Program, Acute and Chronic Thromboembolic Disease Program, Pulmonary and Critical Care Division, Division of Pulmonary, Critical Care, & Sleep Medicine, David Geffen School of Medicine at UCLA, 650 Charles E. Young Drive South 43-229 CHS, Los Angeles, CA 90095-1690, USA.
³ Pulmonary Vascular Disease Program, Acute and Chronic Thromboembolic Disease Program, Pulmonary and Critical Care Division, Division of Pulmonary, Critical Care, & Sleep Medicine, David Geffen School of Medicine at UCLA, 650 Charles E. Young Drive South 43-229 CHS, Los Angeles, CA 90095-1690, USA. Electronic address: rchannick@mednet.ucla.edu.

PMID: 34809914
DOI: 10.1016/j.ccl.2021.08.002

Abstract

Pulmonary arterial hypertension is a rare disease characterized by pulmonary microvasculature remodeling leading to right ventricular failure and death. Medical management of pulmonary hypertension has grown increasingly complex as more therapeutic agents have been developed. Evolving treatment strategies leveraging the endothelin, nitric oxide, and prostacyclin pathways lead to improved exercise capacity and outcomes in patients; however, significant opportunities for advancement remain.

Keywords: Medical management; Pulmonary arterial hypertension; Pulmonary hypertension; Therapy; Treatment.

Publication types

Review

MeSH terms

Antihypertensive Agents / therapeutic use
Heart Failure*
Humans
Hypertension, Pulmonary* / drug therapy
Hypertension, Pulmonary* / epidemiology
Pulmonary Arterial Hypertension*

Substances

Antihypertensive Agents